Avanza Fonder AB Has $1.88 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Avanza Fonder AB lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 23.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,761 shares of the medical research company’s stock after selling 3,210 shares during the period. Avanza Fonder AB’s holdings in IQVIA were worth $1,876,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after purchasing an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after buying an additional 712,958 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock worth $818,315,000 after buying an additional 77,981 shares in the last quarter. Invesco Ltd. increased its holdings in shares of IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock worth $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after buying an additional 59,426 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the subject of several recent analyst reports. Mizuho dropped their price objective on shares of IQVIA from $210.00 to $190.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a report on Monday, May 19th. Hsbc Global Res cut shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Barclays decreased their price target on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Finally, Redburn Partners set a $188.00 price target on shares of IQVIA in a research note on Friday, May 23rd. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $226.32.

IQVIA Trading Down 0.6%

IQV opened at $158.82 on Thursday. The firm’s fifty day moving average is $147.21 and its two-hundred day moving average is $178.30. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $27.48 billion, a PE ratio of 21.18, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the business posted $2.54 earnings per share. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.